Journal ArticleDOI
Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
A. John Rush,Madhukar H. Trivedi,Stephen R. Wisniewski,Andrew A. Nierenberg,Jonathan W. Stewart,Diane Warden,George Niederehe,Michael E. Thase,Philip W. Lavori,Barry D. Lebowitz,Patrick J. McGrath,Jerrold F. Rosenbaum,Harold A. Sackeim,David J. Kupfer,James F. Luther,Maurizio Fava +15 more
Reads0
Chats0
TLDR
The acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial are described and compared.Abstract:
Objective: This report describes the participants and compares the acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Method: A broadly representative adult outpatient sample with nonpsychotic major depressive disorder received one (N=3,671) to four (N=123) successive acute treatment steps. Those not achieving remission with or unable to tolerate a treatment step were encouraged to move to the next step. Those with an acceptable benefit, preferably symptom remission, from any particular step could enter a 12-month naturalistic follow-up phase. A score of ≤5 on the Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR 16 ) (equivalent to ≤7 on the 17-item Hamilton Rating Scale for Depression [HRSD 17 ]) defined remission; a QIDS-SR 16 total score of ≥11 (HRSD 17 ≥14) defined relapse. Results: The QIDS-SR 16 remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, t...read more
Citations
More filters
Journal ArticleDOI
Predicting Treatment Response to Antidepressant Medication Using Early Changes in Emotional Processing.
Michael Browning,Michael Browning,J Kingslake,Colin T. Dourish,Guy M. Goodwin,Catherine J. Harmer,Gerard R. Dawson +6 more
TL;DR: Changes in emotional processing can provide a sensitive early measure of antidepressant efficacy for individual patients and may be used to guide antidepressant therapy and reduce the time taken for depressed patients to return to good mental health.
Journal ArticleDOI
Long‐term efficacy of repeated daily prefrontal transcranial magnetic stimulation (tms) in treatmnt‐resistant depression
Antonio Mantovani,Antonio Mantovani,Martina Pavlicova,David H. Avery,Ziad Nahas,William M. McDonald,Chandra Wajdik,Paul E. Holtzheimer,Mark S. George,Mark S. George,Harold A. Sackeim,Sarah H. Lisanby +11 more
TL;DR: This study examined the long‐term durability of clinical benefit from TMS using a protocol‐specified TMS taper and either continuation pharmacotherapy or naturalistic follow‐up.
Journal ArticleDOI
A neuroscientific update on monoamine oxidase and its inhibitors
TL;DR: The basic science and function of the monoamine oxidase system and some proposed neuropsychiatric symptoms that may arise if this enzyme system is altered by genetic predisposition are focused on.
Journal ArticleDOI
Transcranial focused ultrasound as a possible treatment for major depression.
TL;DR: Transcranial focused ultrasound (tFUS), a novel technique to deliver highly focused acoustic energy to a small brain region, has been used for targeted drug delivery by increasing blood-brain barrier permeability, and it can noninvasively focally modulate human cortical function.
Journal ArticleDOI
Vagus Nerve Stimulation (VNS) and Other Augmentation Strategies for Therapy-Resistant Depression (TRD): Review of the Evidence and Clinical Advice for Use
Helge H. O. Müller,Sebastian Moeller,Caroline Lücke,Alexandra P. Lam,Niclas Braun,Niclas Braun,Alexandra Philipsen +6 more
TL;DR: This mini-review provides a comprehensive overview of augmentation pharmacotherapy and neurostimulation-based treatment strategies, with a special focus on VNS in TRD, and provides practical clinical advice for how to select TRD patients for add-on neuro Stimulation treatment strategies.
References
More filters
Journal ArticleDOI
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice
Madhukar H. Trivedi,A. John Rush,Stephen R. Wisniewski,Andrew A. Nierenberg,Diane Warden,Louise Ritz,Grayson Norquist,Robert H Howland,Barry D. Lebowitz,Patrick J. McGrath,Kathy Shores-Wilson,Melanie M. Biggs,Goundappa K. Balasubramani,Maurizio Fava +13 more
TL;DR: The response and remission rates in this highly generalizable sample with substantial axis I and axis III comorbidity closely resemble those seen in 8-week efficacy trials.
Journal ArticleDOI
The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.
A. John Rush,Madhukar H. Trivedi,Hicham M. Ibrahim,Thomas J. Carmody,Bruce A. Arnow,Daniel N. Klein,John C. Markowitz,Philip T. Ninan,Susan G. Kornstein,Rachel Manber,Michael E. Thase,James H. Kocsis,Martin B. Keller +12 more
TL;DR: The QIDS-SR(16) has highly acceptable psychometric properties, which supports the usefulness of this brief rating of depressive symptom severity in both clinical and research settings.
Journal ArticleDOI
Cross-Validation of Item Selection and Scoring for the SF-12 Health Survey in Nine Countries: Results from the IQOLA Project
Barbara Gandek,John E. Ware,Neil K. Aaronson,Giovanni Apolone,Jakob B. Bjorner,John Brazier,Monika Bullinger,Stein Kaasa,Alain Leplège,Luis Prieto,Marianne Sullivan +10 more
TL;DR: In this article, the authors compared the SF-12 and SF-36 summary measures in nine European countries (Denmark, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, and the United Kingdom).
Journal ArticleDOI
Cumulative illness rating scale.
TL;DR: A Cumulative Illness Rating Scale, designed to meet the need for a brief, comprehensive and reliable instrument for assessing physical impairment, has been developed and tested and is well suited to a variety of research uses.
Journal ArticleDOI
The Inventory of Depressive Symptomatology (IDS): Psychometric properties.
TL;DR: Analysis of sensitivity to change in symptom severity in an open-label trial of fluoxetine showed that the IDs-C and IDS-SR were highly related to the 17-item Hamilton Rating Scale for Depression.